UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges

Cancers, 2023-02, Vol.15 (4), p.1130

2023

Link zum Volltext

Verfügbarkeit prüfen

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359221146129-17588359221146129

2023

Link zum Volltext

Verfügbarkeit prüfen

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment

Cancers, 2023-01, Vol.15 (3), p.767

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50

Frontiers in oncology, 2022-08, Vol.12, p.980765-980765

2022

Link zum Volltext

Verfügbarkeit prüfen

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review

Current oncology (Toronto), 2021-08, Vol.28 (5), p.3384-3392

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241249602-17588359241249602

2024

Link zum Volltext

Verfügbarkeit prüfen

530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A603-A604

2023

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

Expert opinion on biological therapy, 2023-11, Vol.23 (11), p.1039-1042

2023

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?

Expert opinion on investigational drugs, 2022-08, Vol.31 (8), p.855-874

2022

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers for Antibody-Drug Conjugates in Solid Tumors

Molecular cancer therapeutics, 2024-04, Vol.23 (4), p.436

2024

Link zum Volltext

Verfügbarkeit prüfen

Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?

The lancet oncology, 2022-03, Vol.23 (3), p.325-328

2022

Link zum Volltext

Verfügbarkeit prüfen

Emerging treatment landscape of non-muscle invasive bladder cancer

Expert opinion on biological therapy, 2022-06, Vol.22 (6), p.717-734

2022

Link zum Volltext

Verfügbarkeit prüfen

The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

Expert opinion on investigational drugs, 2022-11, Vol.31 (11), p.1203-1226

2022

Link zum Volltext

Verfügbarkeit prüfen

The immunogram of inflammatory breast cancer

Cancer treatment reviews, 2023-09, Vol.119, p.102598-102598, Article 102598

2023

Link zum Volltext

Verfügbarkeit prüfen

Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?

European journal of cancer (1990), 2022-08, Vol.171, p.25-42

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment optimization in early triple negative breast cancer

Expert review of anticancer therapy, 2023-10, Vol.23 (10), p.1107-1116

2023

Link zum Volltext

Verfügbarkeit prüfen

Effect of the mode of delivery on the risk of endometriosis recurrence: a retrospective cohort study

Fertility and sterility, 2022-12, Vol.118 (6), p.1080-1087

2022

Link zum Volltext

Verfügbarkeit prüfen

Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center

European journal of cancer (1990), 2024-01, Vol.196, p.113423-113423, Article 113423

2024

Link zum Volltext

Verfügbarkeit prüfen

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

European journal of cancer (1990), 2023-09, Vol.190, p.112944-112944, Article 112944

2023

Link zum Volltext

Verfügbarkeit prüfen

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Cancer treatment reviews, 2024-07, Vol.128, p.102761-102761, Article 102761

2024

Link zum Volltext

Verfügbarkeit prüfen

Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population

The oncologist (Dayton, Ohio), 2024-02, Vol.29 (2), p.e266-e274

2024

Link zum Volltext

Verfügbarkeit prüfen

New Concepts in Cardio-Oncology

Breast Cancer Research and Treatment, 2023, Vol.188, p.303-341

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting HER2 heterogeneity in breast and gastrointestinal cancers

Trends in cancer, 2024-02, Vol.10 (2), p.113-123

2024

Link zum Volltext

Verfügbarkeit prüfen

Variant allele frequency: a decision-making tool in precision oncology?

Trends in cancer, 2023-12, Vol.9 (12), p.1058-1068

2023

Link zum Volltext

Verfügbarkeit prüfen

Cardiotoxicity of Agents Used in Patients With Breast Cancer

JCO oncology practice, 2024-01, Vol.20 (1), p.38

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)
Buchkapitel
(2)

Sprache

Englisch
(29)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50

Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review

Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment

530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

Antibody-drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?

Biomarkers for Antibody-Drug Conjugates in Solid Tumors

Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?

Emerging treatment landscape of non-muscle invasive bladder cancer

The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

The immunogram of inflammatory breast cancer

Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?

Treatment optimization in early triple negative breast cancer

Effect of the mode of delivery on the risk of endometriosis recurrence: a retrospective cohort study

Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population

New Concepts in Cardio-Oncology

Targeting HER2 heterogeneity in breast and gastrointestinal cancers

Variant allele frequency: a decision-making tool in precision oncology?

Cardiotoxicity of Agents Used in Patients With Breast Cancer

Suchergebnisse filtern